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Training for details produces tunnel vision,
and men of broader perspective are required
for useful application of scientiﬁc progress.
Michael Shimkin
Nearly every day, the issue of liver transplanta-tion (LT) for hepatocellular carcinoma(HCC) is debated worldwide during rounds,
publications, meetings, and—more importantly—in
front of patients with liver cancer who are seeking their
doctors’ advice, often after the digital information
media have left them and their families empty-handed.
Physicians have realized how their certainties can
weaken and can strongly differ, regardless of whether
the prediction of post-LT outcome is applied to large
populations or to single individuals with liver cancer.
In addition, liver-dedicated physicians with nontrans-
plantation expertise may ﬁnd themselves puzzled when
dealing with the existing restrictions on the distribu-
tion of the scarce resource of donated organs.(1-3) Allo-
cation rules are in fact continuously released based on
adjustments adopted within the transplantation com-
munity to maximize patient beneﬁt—deﬁned as an
improvement in quantum of life in each patient inde-
pendent of tumor stage—while avoiding harm to other
patients who are waiting for a liver graft. Putting this
into practice, the mission of doing justice in transplan-
tation is attempted either through application of the
utility principle (i.e., when organs are allocated to
patients who have the best post-LT predicted survival)
or in adherence to the mandate to care for the “sickest
patient ﬁrst.”(4)
In transplantation candidates with HCC, the main
obstacle to a smooth organ allocation is the lack of
instruments able to determine, with sufﬁcient detail,
exactly how sick a patient is, how speciﬁc a given
tumor presentation is, and how likely the tumor
response to various treatments will be. Scores modu-
lated on HCC characteristics have been proposed,(4-8)
but the estimation of the risk of pretransplantation
dropout or posttransplantation beneﬁt remains subop-
timal. What is missing to fully accomplish the “nearly
impossible mission” to frame the complex scenario of
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LT for HCC is the ability to capture, in a weighty
manner, the evolution of a given cancer in relation to
treatment, as this could be the main driver to predict
posttransplantation outcome in patients who have cir-
rhosis with HCC, similarly to what the Model for
End-Stage Liver Disease (MELD) system does in
noncancer candidates. Notably, the lack of precise
prognostication tools for transplantation candidates
with HCC has been repeatedly reported as causing
detrimental effects for non-HCC patients, who may
be disfavored by unbalances in points systems that
oversupply cancer patients.(4,9)
Looking at the magnitude of the information pre-
sented on LT for HCC and at its diffuse interpreta-
tion, any further attempt to create new prognostication
scores seems inadequate unless a precise description of
the objective granularity of tumor presentation and of
its spectrum of responses to different treatment options
is taken into account. Also, as modern discussions on
LT in HCC move into the broaden concept of a medi-
cine made of economic, social and ethical components,
a more accountable description of the tumor condi-
tions could be instrumental to move the scale of prior-
ities into a more realistic and treatment-oriented
approach to HCC.
Priority in organ allocation and patient selection are
crucial factors that are difﬁcult to merge because they
have endpoints that are inherently far from one
another. Optimization of a given resource in the case
of organ allocation and maximization of outcomes
when patient selection is targeted are in fact the driving
forces that tend to split LT for HCC apart. Yet the
attempt to reconcile these postulates is often referred
to as an effort to “square the circle.”
In this article, the impossible task to square the
closed circle of patient selection and graft allocation in
LT for HCC is approached as it would be during a
math class, solving this same problem by multiplying
the square of the radius (r2) by p: an irrational number
(i.e., a number that never ends) used to approximate a
solution that otherwise would be to the inﬁnitum. To
do this, a comprehensive assessment of HCCs exam-
ined for transplantation is proposed.
In the proposed model, tumor presentation and
response to therapy are used as a “p”: a sort of rec-
tifying factor to be used within the challenging con-
texts of listing and prioritization, with the aim of
improving their mutual efﬁciency in optimizing
patient outcome and resource allocation in the ﬁeld
of LT for HCC.
Background: The Fruits of
Long Endeavors
The likelihood of patient survival after transplanta-
tion remains an essential criterion when deciding on
LT for HCC and represents the most important factor
for indicating such a demanding therapeutic
option.(1,3,4,10) About two decades ago, the Milan cri-
teria deﬁned the benchmark for achieving the best
post-LT survival in HCC.(11) Since then, these
restricted criteria (single nodule 5 cm or multiple
[3] nodules 3 cm in size) have become the best pre-
dictor of excellent post-LT outcome and cost-effective
transplantation. This result strongly inﬂuenced staging
systems for HCC, guidelines, recommedations, and
allocation policies for deceased donor liver grafts.(12-14)
Starting with the University of California San Fran-
cisco (UCSF) criteria (single nodule 6.5 cm; 2 to 3
lesions each 5 cm or 4 to 5 lesions each 3 cm, with
the maximum sum of diameters 8 cm in all cases)(15)
multiple other metrics have been established over time
in an attempt to predict the results of LT for HCC.(16)
Most of these metrics have shown the same good sur-
vival results achieved when restricted indications were
met, even though subsequent observations revealed a
progressively increased rate of cancer recurrence in
tumors transplanted beyond conventional limits.
Clearly, the expanded criteria mechanism built on
pure morphologic tumor indexes (i.e., largest diameter
and number of tumor nodules) did not help in deﬁning
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which patients with cirrhosis and HCC beyond the
Milan criteria should be offered LT ﬁrst, but did unravel
the negative prognostic inﬂuence of biological and path-
ological features rarely observed in patients meeting
conventional criteria (such as high alpha-fetoprotein
[AFP] serum level, presence of microvascular invasion,
and poorly differentiated [G3] tumors).(4,16)
Conventional selection criteria have persisted, how-
ever, in guidelines and organ procurement organization
policies, while the “transplantable HCC” category (i.e.,
curable with transplantation only) has been enriched
over time, with cases at worse prognosis (i.e., T3 stage
according to the United Network for Organ Sharing
[UNOS] system) deﬁned as transplantable on the basis
of local dynamics of the waiting list that did not preju-
dice other noncancer recipients with a better progno-
sis.(17) It is conceivable that 25%-40% of the current
HCC patients listed for LT belong to such a T3 sub-
group receiving exception points and presumably some
form of tumor downstaging.(4,18)
The introduction of direct antiviral agents in daily
practice(19) will further increase organ availability for
patients with HCC in the near future, as a signiﬁcant
number of patients with decompensated cancer-free
hepatitis C virus (HCV) cirrhosis will likely be inacti-
vated and delisted within 1 year just by the introduction
of second-generation direct antiviral agents. In a recent
multicenter European study, it was estimated that 33%
and 25% of HCV cancer-free listed cirrhosis will be
inactivated or delisted, respectively.(20) In parallel, the
practice of downstaging tumors in patients who were
originally thought to be ineligible for transplantation(21)
will increase the number of borderline HCC cases pre-
sented to liver transplantation boards for decision.
Emboldened by its own success, transplantation for
HCC—a neglected indication just 20 years ago—is
likely to become the leading indication for liver
replacement in the near future.
The Inverse Perspective of
Case Selection: From
Tumor Presentation to
Response to Therapy
Tumor subclasses correlating with diverse molecular
assays and clinicopathologic behavior have been discov-
ered progressively,(22,23) with gene signatures also play-
ing a role in the prognostication of LT patients beyond
the Milan criteria.(24) However, the extreme molecular
heterogeneity of HCC still represents a signiﬁcant limi-
tation to the full introduction of precision medicine in
patients within the transplantation landscape.(23)
Despite the absence of reliable biomarkers or genetic
alterations inﬂuencing clinical decisions, a different kind
of individualized medicine has progressively gained
credit from multidisciplinary tumor board discussions in
which all tumor and individual characteristics of each
patient are weighed by different specialties and routed
to variegated therapeutic alternatives. Perhaps the less
known but most relevant result of this approach is the
inverse perspective that has emerged in centers with a
large referral of HCC patients regardless of their indica-
tion for transplantation.
In practice, rather than considering up front patients
with HCC as being eligible for LT according to dis-
ease presentation, most patients with HCC remain
within the spectrum of eligibility for LT—the exclu-
sions determined only by macrovascular invasion,
extrahepatic spread, comorbidities, and age beyond
limits—and are assigned to different forms of com-
bined therapy that, if sufﬁciently effective within a cer-
tain time, may allow liver transplantation listing.
A ﬂexible approach aimed at merging tumor stage
and results of treatment is going to be adopted in a
large European region(25) and is based on the observa-
tions that post-LT survival outcomes in HCC beyond
Milan criteria with objective and sustained response to
pre-LT therapy are not signiﬁcantly different com-
pared with those patients who meet conventional crite-
ria at presentation.(17) In order to avoid the risks of
uncontrolled expansion of HCC criteria, such an
“inverse selection approach” based on response to ther-
apy requires a few restrictions:
 All suitable patients with cirrhosis who have treatable
HCC by nontransplantation means should be
treated, regardless of whether LT is in their therapeu-
tic future. The best available option (i.e., monother-
apy or combination therapy) should be determined
after thorough multidisciplinary discussion.
 A minimal observation period after the conclu-
sion of a given (combination) treatment is man-
datory, because time is a surrogate of tumor
aggressiveness and therefore an additional factor
in the selection process.(17,21,23) Time as a covari-
ate is also required to assess tumor response and
evolutionary posttreatment outcome.(23)
 All possible information on tumor biology should
be collected and discussed before the board.
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With this particular aim, absolute values and var-
iations of AFP serum levels over time, as well as
tissue biopsies (obtained during percutaneous
ablation, laparoscopic staging, or resection),
should be collected.(26)
 The minimal expected survival for patients under-
going LT under this conditions should be
increased from the conventional limit of 50% at 5
years to 60% or higher. In doing so, the benefit
achievable in HCC beyond conventional criteria
could be adjusted to acceptable levels of posttrans-
plantation utility(4,7,25) while avoiding any harm to
patients who remain on waiting lists.(17,27,28)
Transplantable Tumors
Based on these and other observations, a possible
reappraisal of patients with HCC who are eligible for
and curable with transplantation could be attempted
within a comprehensive frame able to capture the large
majority of tumor presentations and describe in a sim-
pliﬁed manner the granularity of possible responses to
therapy. Figure 1 presents a scale of HCC disease
severity that is designed to prioritize classes capable of
routing organ allocation by means of points systems
determined according to national and regional scenar-
ios. Accordingly, transplantable tumors (TTs) will be
deﬁned following the Milan, UCSF, or expanded cri-
teria together with the donor rate in each allocation
area, the proportion of enlisted HCC/non-HCC
patients and the dynamic of the waiting list.
Classes of progression within TTs range from
patients with “zeroed” HCC (i.e., disease completely
removed by surgery, ablation, or embolo-therapies) to
patients carrying conventional criteria tumors either at
diagnosis or as late recurrence (after >2 years from a
previous curative treatment) considered as de novo can-
cers on cirrhotic oncogenic livers rather than intra-
hepatic metastases.(23,29) Finally, patients in whom
transplantable criteria are still met—whether at incep-
tion or after complete or near-complete response to
downstaging treatment—should be ranked as the high-
est priority. These are patients who have achieved a sub-
optimal response (i.e., a partial response) despite
adequate locoregional treatment or patients presenting
with early cancer recurrence (2 years from a previous
curative treatment) and whose cumulative tumor staging
still correspond to a potentially transplantable tumor.
The main principles governing what can be called an
adaptive approach are summarized in Table 1, which
should be consulted in conjunction with Figure 1.
                                                                                                                                      
FIG. 1. Staging and allocation for HCC within the spectrum of LT eligibility. Classes of progression and allocation priority within
the TT stages identiﬁed for HCC in well-compensated cirrhosis. LT eligibility and priority are not determined completely up front,
but they both come into focus after the best available therapy has been applied. Details on application rules are given in Table 1.
                                                                                                                                      
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Following the line of reasoning proposed in this
approach, the heterogeneities of HCC’s presentations
and treatments are routed into different subclasses that
include current standards, variations in local capabilities
and resource allocation, and evolutionary conditions
related to treatment response, as well as HCC tumor
recurrence, AFP ﬂuctuations, and objective tumor
assessment with up-to-date radiology criteria.(30-32)
Although with different relative weight, all these condi-
tions play a role in the current decision-making on LT
TABLE 1. Application Rules for Staging and Allocation
1 The system applies only to early and intermediate stage HCC presenting in compensated cirrhosis/chronic liver diseases (stages BCLC-A and
BCLC-B). Exclusion criteria are vascular invasion, extrahepatic spread and comorbidities. HCC arising in decompensated (Child-Pugh class
C) cirrhosis is determined by laboratory MELD score and receives priority accordingly.
2 In principle, any HCC arising in compensated cirrhosis is considered as TT once inclusion/exclusion criteria are satisfied. Morphology criteria
(i.e., tumor size and number) used for transplantation eligibility should be defined a priori at a regional level depending on the dynamics of
the waiting list, proportion of enlisted HCC versus non-HCC patients, harm to patients who remain on the waiting list, donor availability,
etc., and should not be modified at any time during patient follow-up (i.e., up to LT, dropout, or death). Morphology criteria reported objec-
tively should be integrated with pathologic/biologic information (e.g., tumor biopsy, AFP levels) when available, and all information should
be discussed before the tumor transplantation board (see points 3 and 4 below). AFP cutoff levels able to exclude transplantation eligibility
even in presence of permissive tumor morphology conditions should be defined a priori as well, as that limit currently ranges from 200 to
1000 ng/mL(21,32,39,41-43) or according to steady increase over time.(32)
3 All TT should be treated with the single/combined best available treatment according to internal protocols and/or accepted guidelines and
should be reconsidered for class assignment at the end of each treatment course. Accordingly, any decision regarding treatment of a TT
should take into account the transplantation implications before and after therapy courses.
4 Reproducible criteria for imaging, diagnosis, classification, and reporting in HCC before and after treatment should follow common accepted
standards determined a priori(30,31) and should also consider the contribution of tumor growth rate(49) and patterns of residual disease
determination.(50) Digital imaging should be accessible for internal or external audits.
5 If TT are not treatable due to technical or medical reasons not captured by MELD score (i.e., ascites), the patient should be classified as hav-
ing untreatable HCC (TTUT) and prioritized accordingly.
6 Point assignment and priority class should be managed dynamically, because disease status may change over time depending on biology
and therapy. Stepwise assessments should be undertaken at a minimum of four possible time points:
a) at tumor presentation (baseline assessment), if TT meets points n.1 and 2 above;
b) in stabilized tumor conditions (i.e., stable disease for a sufficient period of time [at least 3 months])(7,17,21);
c) in case of tumor progression during treatment;*
d) at the end of each treatment course.
7 Patients included in downstaging protocols should be considered as TT0NT (intermediate priority) in case of complete response at the end of
treatment—due to the initial tumor stage exceeding conventional criteria—or as TTDR (high priority) in case of suboptimal downsizing and/
or residual tumor remaining reasonably stable over time in patients still meeting transplantation criteria. For patients included in “extended
limits for downstaging” protocols, LT listing could be considered only after complete response and if part of prospective investigations.
8 Because changes that occur in serum AFP levels while patients are on the waiting list correspond closely to changes in posttransplantation
mortality,(51) AFP trends should parallel radiologic tumor response (or progression) of a transplantable tumor during treatment and/or
follow-up. In principle, patients who have a major drop in AFP level after treatment should be considered at a more significant level than
those who do not. In patients included in downstaging protocols (see point 7 above), differential drop and absolute APF level could help in
discriminating various levels of response—and priority-among different patients with similar radiology-assessed posttreatment response.
9 Recurrent HCC should be approached similarly to na€ıve HCC, with identical treatment aims and general requirements as listed above
in points 1-5. Recurrent HCC may be classified as TTFR or TTDR according to the time of recurrence, whether this is 2 years (i.e., early
recurrence) or >2 years (i.e., late recurrence) from the original curative treatment. This yields different priorities because of the higher risk
of dropout in early recurring tumors.
 Early recurrences should be listed only if the tumor meets transplantable criteria both at the time of original treatment and after cumula-
tive staging, which is calculated at the time of transplantation consideration. The cumulative stage of an early recurring HCC considers
one tumor entity as the sum of the first presenting HCC 1 recurrent tumor.
 Late recurrences should be listed if meeting transplantation criteria at the time of transplantation consideration, as they could be rated as
TTFR regardless of the stage of the first-presenting HCC curatively removed >2 years ago.
10 Exceptions to the general frame of stage progression and priorities are allowed with approval from a regional reviewer board. In the current scenario,
exceptions may be related to: experimental de principe transplantation strategies applied to resected tumors (TT0c); observational strategies paus-
ing treatment for <2 cm lesions (TT1); downgrade in priority for recurrent although nontreatable HCCs; complete posttreatment responses of seg-
mental portal vein thrombosis; and salvage surgery to achieve complete response in TTPR tumors (and consequent reduction in TTNT stage, etc.).
Rules apply to the system shown in Fig. 1.
*HCC progression should be rated in order of severity as (A) progression of the treated tumor; (B) appearance of an additional nodule;
(C) evidence of vascular invasion; or (D) extrahepatic tumor spread. In this model, tumor progression types A and B may indicate fur-
ther treatment, upgrade in priority, or dropout depending on whether the detected progression still meets transplantation criteria; pro-
gression types C and D exclude the patient from transplantation consideration (i.e., dropout from the waiting list).
HEPATOLOGY, Vol. 63, No. 5, 2016 MAZZAFERRO
1711
for HCC and are incorporated in a system in which
transplantation eligibility and priority are not completely
determined up front but they both come into focus after
all relevant components have been considered and ther-
apy has been applied.
Such a deﬁnition of a “transplantable tumor” is inher-
ently open to more speciﬁc contribution of staging and
allocation updates and is in line with recent UNOS poli-
cies of HCC exceptions, in which inclusive tumor sub-
classes of “growing,” “treated,” and “exceeding T2” have
been identiﬁed to increase convergence among tumor
staging parameters and points in priority (i.e., classes 5A-
g, 5T, and 5X in the Organ Procurement and Transplan-
tation Network [OPTN] Policy 2015) for liver allocation
in HCC(1) in which standardized radiology criteria for
imaging, diagnosis and classiﬁcation are incorporated.(31)
Priority as a Function of
Allocation Principles
Questions may arise regarding the scale of priority
in the proposed approach. Indeed, priority itself is a
concept with several practical applications, depending
on which allocation principle prevails. In addition, the
priority endpoints may be weighted differently, rang-
ing from the minimization of pre-LT risk to drop out
(or death) when the urgency principle is adopted to the
maximization of post-LT outcome in case the utility is
targeted, particularly for the transplantation beneﬁt—
namely, the net survival obtained by subtracting the
survival achieved with LT by the survival obtainable
with nontransplantation options.(23,33,34)
In addition, patients, physicians, and society at large
signiﬁcantly inﬂuence the perception of priority as well
as decision-making with subjective convictions. Com-
plex statistical models have been advocated to balance
all of these components; however, controversies persist,
because within this context even a very light shift in
the design of surveys or variation in predetermined
assumptions lead to quite different conclusions.(33-35)
In the proposed concept of TTs, a series of relatively
straightforward observations support the existence of a
continuity in HCC subgroups whose severity—and con-
sequently priority—evolves, not only as a consequence of
tumor biology, but also as a product of medical and sur-
gical interventions. The list of premises upon which each
priority class is identiﬁed is summarized in Table 2.
After all, the apparent distance between the assump-
tions deﬁning each priority class can be normalized
through composite evaluations of the need of trans-
plantation that correspond to a stepwise increment of a
numeric point scale. Obviously, the entity of progres-
sion into the priority scale has to be determined at a
regional and/or national level.
Selection and Allocation
Principles Reconciled: Has
the Circle Been Squared?
Over the years, the growing number of analyses advo-
cating adjustments not just in selection but also in allo-
cations rules for LT in HCC, has elicited the current
effort to place transplantation decisions for patients with
HCC within a modern perspective. The assumption is
that transplantation eligibility and allocation in HCC
could be moderately loosened without undue prejudice
to other recipients; this is very likely to occur, as we will
soon witness a net decrease in transplantation indication
for HCV-related cirrhosis and an increase in the prac-
tice of downstaging HCC. The proposed system might
be capable of transforming downstaged tumor responses
from exceptions to drivers for both the selection and
allocation processes (Table 1, points 7 and 8).
The attempt to square the circles and reconcile tumor
stage, effects of treatment, and priority in allocation is
by deﬁnition imperfect, and there is an actual risk that
several factors may render this proposal into wishful
thinking. In order to consolidate the model, the follow-
ing important areas will need to be implemented.
SYSTEM SOLIDITY AND
FLEXIBILITY SHOULD BE
REINFORCED
Although inclusive by all means, the application of
the proposed model of priority leans slightly toward
transplantation beneﬁt (i.e., utility-based) end-
points.(4,23,33,34) This may be criticized by those who
consider crude long-term survival as a more important
target to be achieved compared with life-years
gained.(17,36) However, the redeﬁnition of transplantable
HCC by way of pretransplantation treatment, rather
than precluding ideal transplantation candidates from
such a curative option simply delays their priority in
favor of patients who are still within transplantation cri-
teria but are at a higher risk of dropout due to tumor
progression or incomplete response at the end of suc-
cessful treatment courses (see also Table 1). In fact, a
beneﬁt-oriented approach combines both pre- and
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posttransplantation outcomes, integrates the results of
alternative treatment strategies, makes obvious the unac-
ceptable survival targets for transplantation, and allows a
comparison between patients with and without
HCC.(7,23,29) Following the same line of reasoning, a
variable age threshold beyond which the net beneﬁt for
HCC patients does not justify LT over resection or abla-
tion seems questionable, at least until a transplantation-
versus nontransplantation-related beneﬁt comparison is
adjusted on reference cohorts derived from the general
population matched by sex, age, and years of diagnosis.
It is worth noting that within the context of patient ben-
eﬁt, both the absolute number of years of life gained and
years of life lost with respect to life span (i.e., relative sur-
vival) should be considered when assessing the efﬁcacy
of surgical therapies offered to older patients.(37)
Conversely, a more realistic wait time and priority
score based on assumptions shown in Table 2 could
silence both the utilitarian and urgency aims while
including patients and societal perspectives—a process
that seems essential to improve the ﬂexibility of the
transplantation system in HCC with respect to non-
cancer indications.
COMMON CRITERIA FOR
STAGING, TREATMENT, AND
RESPONSE ASSESSMENT SHOULD
BE ADOPTED
In the proposed system, each patient with HCC
who has reasonably stable cirrhosis stays within the
heterogeneous group of TTs while staging and priority
TABLE 2. Staging and Priority Classification of HCC in the LT Setting: Patient Stratification According to Allocation Principles
TT Categories
Priority According to
HCC Dropout Models
Priority According to
Transplantation Benefit
Priority Perception of Patient
and Societal Expectations
TT0C Very Low Low Low
No residual tumor after
curative treatment of HCC
Very low risk of dropout in cured HCC Transplantation benefit depends
on MELD score only
The patient should not
undergo transplantation
TT0L Low-Intermediate Low Intermediate
No residual tumor after
locoregional embolo-therapies
for transplantable HCC
Low risk of dropout in cured HCC Transplantation benefit depends
on HCC-MELD
The patient was eligible for
transplantation but can be
placed on hold because the
tumor seems to be cured
TT1 Low Low Low
Single HCC 2 cm Low risk of dropout in very early HCC Low benefit in presence of
alternative nontransplantation
treatments
The patient should not undergo
transplantation if there are
other treatment options
TT0NT Not Applicable Low Low
No residual tumor after
treatment of a nontransplantable
HCC (successful downstaging)
NT HCC should not be listed up front,
similarly to non-HCC in patients
with low MELD scores
Transplantation benefit depends
on MELD score only
The patient was not eligible for
transplantation and has been
cured by other means
TTFR Intermediate Intermediate High
Transplantable HCC > T1 at
first presentation or recurrent
HCC >2 years after curative
treatment
Demonstrated increase of dropout risk
over time for both size and
number parameters
Benefit depends on true
applicability of alternative
treatments
This patient has the best
posttransplantation
survival (utility)
TTUT Intermediate High High
Transplantable HCC judged
untreatable for reasons not
captured by MELD (i.e., ascites)
Increased dropout risk; short time to
liver decompensation
There is no therapeutic
alternative for HCC
The patient is expected to have
good utility posttransplantation
TTPR Intermediate/High High High
Partial response after complete
bridge therapy in a transplantable
tumor
Risk of selection of biologically
aggressive clones with increased
proliferative activity
Failure of a bridge therapy with
no residual therapeutic alternative
The patient is expected to have
good utility posttransplantation
TTDR Intermediate/High High High
Transplant eligibility after
downstaging (sustained partial
response) or recurrent HCC
<2 years after curative treatment
of any HCC
High dropout risk over time for both
size and number parameters
Benefit depends on absence of
true alternative treatments
Transplantation should be
offered in relatively stable
patients before it is too late
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is determined according to the results of the applied
therapies. This means that the only condition required
to obtain an optimal result is the management of
patients with similar pretransplantation locoregional
treatments, response, monitoring, and delisting crite-
ria.(17,25,30,31,38) Such practices should be enforced
within each liver allocation system and among HCC
referral centers, as they are essential to help the imple-
mentation of the models detailed above.
TRANSPLANTATION CRITERIA
AND MINIMUM ACCEPTED
SURVIVAL SHOULD BE DEFINED
A precise deﬁnition of transplantation criteria
should be determined a priori within large geographic
regions according to the principles detailed above
(Table 1, point 2). This deﬁnition should incorporate a
minimum expected survival (which should target at
least 50% at 10 years, rather than 5 years) and also the
likelihood of complete/partial response achievable with
nontransplantation treatment strategies.
The use of treatment response as a selection tool
to complement other prognostic pathologic/biologic
covariates in patients exceeding Milan and/or
UNOS criteria appears crucial to promote the use
of expanded HCC criteria on a routine basis. Con-
sidering the unfeasibility of randomized trials in this
ﬁeld, the search for a credible hierarchy within the
expanded criteria (i.e., up to seven, total tumor vol-
ume, morphology adjusted on AFP(7,23,39,40)) could
be aided by comparing of prospective cohorts gener-
ated by variegated applications of these criteria to
the presented model.
LIMITS FOR DOWNSTAGING
STRATEGIES SHOULD BE
AGREED UPON
Because downstaging is a strategy aimed at select-
ing more favorable tumor biology, the downstaged
HCC population must be a fraction of the total
amount of patients with HCC who have a potential
indication to transplantation. By deﬁnition, down-
staged patients are at higher risk of dropout, and
opposite success rates are observed depending on
whether more restrictive or more relaxed tumor bur-
dens are targeted as endpoints.
Restrictive criteria for downstaging eligibility
should be agreed upon within the framework of the
adopted transplantation criteria. Evidence supporting
this statement has come from the most recent update
of the UCSF downstaging protocol, in which the
upper limit to indicate downstaging was determined
up front (see “Background: The Fruits of Long
Endeavors” section). In this experience, 65% of
patients with HCC were converted to Milan criteria,
whereas only 7.5% of patients had posttransplantation
tumor recurrence.(21)
Whatever strategy of downstaging will be deter-
mined, AFP trends over time should parallel radiologic
tumor response (or progression) during treatment and
at the time of the ﬁnal prelisting assessment. AFP cut-
off levels able to exclude transplantation eligibility even
in the presence of permissive tumor morphology con-
ditions should be deﬁned a priori as well, as that limit
currently ranges from 200 to 1000 ng/mL(21,32,39,41-43)
or according to steady increase over time.(32)
WAITING TIME DURATION AND
POSTTRANSPLANTATION
TUMOR RECURRENCES SHOULD
BE MONITORED
It is well known that HCC variables predicting
dropout from the waiting list are also associated with
poorer posttransplantation survival and a higher tumor
recurrence rate,(44,45) with dropout largely depending
on waiting time length. Therefore, the dynamic shifts
of transplantation candidates with HCC within the
proposed frame implies an even closer monitoring of
waiting times and posttransplantation outcomes. Opti-
mization of waiting list time and post-LT results will
minimize tumor recurrence, even though a minimal
observation time for disease stabilization after treat-
ment is highly suggested, to decrease the risk of select-
ing patients with rapidly progressing lesions. The
length of the “no transplantation” observation period
should be determined on a regional basis and should
consider the current standard of 3 months.(3,46)
Envisioned Future and
Conclusion
To some extent, the history of disease comprises a
metamorphosis in treatments and paradigm shifts
anticipating by far the conclusions of large and struc-
tured clinical investigations. For transplantation in the
particular setting of HCC, this model proposed herein
is consistent with previous reports(47,48) and will surely
undergo validation studies in a large European region
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according to a strategy that is in line with modern per-
spectives of HCC management. Figure 2 summarizes
such a change in perspective as it relates to the two
most paradigmatic conditions in which patients are
within or beyond predetermined transplantation crite-
ria. Even at ﬁrst glance, the envisioned future of these
two conditions appears to be enriched by expansions of
therapeutic options, transplantation selection, listing,
and priority (Tables 1 and 2 provide additional details
in this respect). Future studies are warranted to ascer-
tain whether this perspective may develop into an
implementable system capable of incorporating the
current complexities of HCC management into LT
mechanisms.
Over the last two decades, tangible advancement in
survival and in knowledge of HCC have been fueled
not only by major scientiﬁc achievements but also by
changes in the way physicians have dealt with the role
of LT in liver cancer therapy. The shift in perspective
explained in Figs. 1 and 2 is geared toward maximizing
all tumor and therapy heterogeneities in a model that
utilizes variations in HCC presentation and response
to treatment as adjusting factors to reconcile selection
and allocation logistics, with the ultimate aim of
increasing the beneﬁt, effectiveness, and justice of
transplantation for cancer. As new factors emerge and
show signiﬁcant impacts on HCC, treatment strategies
with an even more pronounced passion for details
should be employed. It is difﬁcult to think of an invest-
ment in transplantation that would have a greater
impact than one that creates robust frames within
which to improve the quality of medical indications
and resource allocation for patients with liver cancer.
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FIG. 2. Paradigm shift in the management of LT in patients with HCC. The multistep process covers the diagnosis of HCC to LT
in patients who are within (A) and beyond (B) the criteria. With respect to the current rules, the proposed system uses tumor response
to bridging or downstaging as the main drivers for patient selection and priority allocation.
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